| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Marketable securities | NaN | NaN | 14,947 | 48,651 |
| Cash and cash equivalents | 128,057 | 152,406 | 169,506 | 169,394 |
| Prepaid expenses and other current assets | 4,709 | 4,802 | 3,712 | 3,085 |
| Total current assets | 132,766 | 157,208 | 188,165 | 221,130 |
| Property and equipment | NaN | 30,276 | NaN | NaN |
| Less accumulated depreciation and amortization | NaN | 21,570 | NaN | NaN |
| Property and equipment, net | 8,120 | 8,706 | 9,303 | 9,521 |
| Right-of-use assets | 56,006 | 57,743 | 59,438 | 61,097 |
| Restricted cash | 5,031 | 5,031 | 5,031 | 5,031 |
| Long-term deposit and other assets | 68 | 101 | 288 | 1,782 |
| Total assets | 201,991 | 228,789 | 262,225 | 298,561 |
| Accounts payable | 2,303 | 1,241 | 6,353 | 4,539 |
| Accrued expenses and other current liabilities | 8,592 | 7,668 | 10,765 | 12,797 |
| Operating lease liability, current portion | 7,438 | 7,167 | 6,904 | 6,288 |
| Deferred revenue, current portion | 1,637 | 2,619 | 5,186 | 7,698 |
| Total current liabilities | 19,970 | 18,695 | 29,208 | 31,322 |
| Other long term liabilities | NaN | NaN | 278 | 113 |
| Operating lease liability, net of current portion | 52,445 | 54,437 | 56,304 | 58,116 |
| Long-term debt and accrued interest | 32,654 | 32,534 | 32,414 | 32,296 |
| Total liabilities | 105,069 | 105,666 | 118,204 | 121,847 |
| Common stock-Voting Common Stock | 6 | 5 | 5 | 5 |
| Common stock-Nonvoting Common Stock | 1 | 1 | 1 | 1 |
| Additional paid-in capital | 630,443 | 627,979 | 625,898 | 622,887 |
| Accumulated other comprehensive loss | NaN | NaN | 2 | -4 |
| Accumulated deficit | -533,528 | -504,862 | -481,885 | -446,175 |
| Total stockholders' equity | 96,922 | 123,123 | 144,021 | 176,714 |
| Total liabilities and stockholders' equity | 201,991 | 228,789 | 262,225 | 298,561 |
TScan Therapeutics, Inc. (TCRX)
TScan Therapeutics, Inc. (TCRX)